Calcimedica to present late-breaking positive data, including a win ratio analysis, from phase 2b carpo trial of auxora™ in acute pancreatitis (ap) at the american college of gastroenterology (acg) 2024 annual scientific meeting

Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose auxora patients versus combined low dose auxora and placebo patients statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose auxora compared to placebo clinically meaningful reduction observed for high dose auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge conference call and webcast to review full data set from the ph2b carpo trial to be held at 12 p.m. et/ 9 a.m.
AP Ratings Summary
AP Quant Ranking